While the anti-CTLA4-mediated expansion of the Tregs offers a solid explanation of the protective function of the intervention against lymphedema, the underlying molecular players remain unclear, as our understanding of the immune checkpoint inhibitors is still incomplete. This evidence concerns the gene CTLA4 and lymphedema.